Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P29371

UPID:
NK3R_HUMAN

ALTERNATIVE NAMES:
NK-3 receptor; Neurokinin B receptor; Tachykinin receptor 3

ALTERNATIVE UPACC:
P29371; Q0P510

BACKGROUND:
The Neuromedin-K receptor, identified by its affinity for neuromedin-K over other tachykinins, is integral to signaling pathways involving G proteins and calcium mobilization. Its alternative names include NK-3 receptor and Neurokinin B receptor, highlighting its role in the tachykinin peptide family.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of the Neuromedin-K receptor could open doors to potential therapeutic strategies for treating Hypogonadotropic hypogonadism 11, a disorder marked by a lack of sexual development and low hormone levels. The receptor's involvement suggests that modulating its activity could provide a novel approach to managing this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.